In vitro activity of BAY 12-8039, a new 8-methoxyquinolone

Chemotherapy
A DalhoffR Endermann

Abstract

BAY 12-8039 is a new 8-methoxyquinolone with antibacterial activity against gram-positive bacteria which is significantly better than those of sparfloxacin or ciprofloxacin. The minimal inhibitory concentrations (MICs) for 90% of methicillin-susceptible Staphylococcus aureus and Staphylococcus epidermidis were 0.062 and 2 mg/l, respectively. The MIC90s for ciprofloxacin-resistant, methicillin-susceptible and methicillin-resistant S. aureus were 8 mg/l. Against the staphylococcal strains tested sparfloxacin was 2-fold and ciprofloxacin > or = 10-fold less active. MIC90s for Streptococcus pneumoniae, Streptococcus pyogenes and Streptococcus agalactiae were 0.125-0.5 mg/l, irrespective of whether strains with diminished ciprofloxacin susceptibility or ciprofloxacin-susceptible strains were tested. Against the streptococci sparfloxacin was 2- to 4-fold less active. Against gram-negative bacteria BAY 12-8039 is almost as active as ciprofloxacin, except for Pseudomonas aeruginosa. Against Bacteroides fragilis, Bacteroides spp. and Clostridium spp. BAY 12-8039 was as active as metronidazole. The bactericidal activity against S. aureus and S. pneumoniae was in contrast to that of the other quinolones tested, penicillin G, amoxicillin+/...Continue Reading

Citations

Jul 15, 1999·The Journal of Antimicrobial Chemotherapy·M DonatiR Cevenini
Mar 16, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·C KrasemannG Tillotson
Mar 16, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·A Dalhoff
Sep 7, 2004·The Journal of Antimicrobial Chemotherapy·Valentin FuhrmannFlorian Thalhammer
Jul 5, 2005·Expert Opinion on Investigational Drugs·A Dalhoff
Mar 25, 2008·Therapeutics and Clinical Risk Management·David Rp Guay
Aug 18, 2009·Expert Review of Anti-infective Therapy·Olaf Burkhardt, Tobias Welte
Nov 12, 2009·British Poultry Science·A Goudah, S M Mouneir
Apr 2, 2013·European Spine Journal : Official Publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society·Simon Matthew GrahamJonathan Sandoe
Jun 18, 2016·Journal of Avian Medicine and Surgery·Ayman Goudah, Sherifa Hasabelnaby
Nov 15, 2017·Drug Delivery and Translational Research·María Sebastián-MorellóAlicia López-Castellano
May 5, 2001·Expert Opinion on Pharmacotherapy·J M Blondeau, G T Hansen
Jun 22, 2000·Medicinal Research Reviews·Q LiL L Shen
Dec 13, 2006·Treatments in Respiratory Medicine·George G ZhanelDaryl J Hoban
Jun 24, 2008·Expert Opinion on Pharmacotherapy·Marc Miravitlles, Antonio Anzueto
Jan 26, 2017·International Journal of STD & AIDS·Yang LiXiao-Hong Su
May 16, 2001·Clinical Pharmacokinetics·J T SullivanA H Heller
Dec 20, 1999·The Journal of Antimicrobial Chemotherapy·A PongC C Sanders
Apr 11, 2003·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·A Dalhoff, F-J Schmitz
Mar 5, 2002·British Journal of Clinical Pharmacology·H StassH Delesen
Sep 21, 2000·The Journal of Antimicrobial Chemotherapy·P Ball
Dec 27, 2005·Antimicrobial Agents and Chemotherapy·Ellie J C GoldsteinHelen Fernandez
Jun 8, 2001·The Journal of International Medical Research·J LorenzUNKNOWN BRONCHIMOX Study Group
Jun 24, 2008·Expert Opinion on Pharmacotherapy·Steven Simoens, Marc Decramer
Jul 23, 2013·Journal of Investigative Surgery : the Official Journal of the Academy of Surgical Research·Lorenzo ZaffiriLuis H Toledo-Pereyra
Nov 2, 2012·Expert Review of Respiratory Medicine·Robert Wilson, Aislinn Macklin-Doherty
Jun 25, 2003·Antimicrobial Agents and Chemotherapy·Satoshi AmeyamaMasahiro Takahata
Dec 11, 1999·The Journal of Antimicrobial Chemotherapy·J M AndrewsR Wise

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Allergy & Infectious Diseases

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Allergy & Infectious Diseases (ASM)

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.